Bile-Derived Exosomal miR-196a/-196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer
Bile-based markers detected early biliary tract cancer in lab studies, potentially catching this aggressive disease at more treatable stages.
Bile-derived exosomal miR-196a and miR-196b are identified and validated as novel biomarkers for biliary tract cancer, with miR-196a achieving AUROC 0.79 alone and 0.88 in combination with serum CA19-9 and CEA in a multi-cohort validation study. Importantly, miR-196a detects early-stage BTC — addressing a critical unmet need given the typically late presentation of biliary malignancies.
What the study was
- Study design
- Validation study (multi-cohort)
- Population
- Patients with biliary tract cancer (BTC) vs controls, Japan
- Sample size
- Training: n=10 BTC + 10 controls (RNA-seq screen); Validation: n=50 BTC + 53 controls (TaqMan PCR); Serum cohort: n=64 BTC + 79 controls
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Cancer Science
Why it surfaced
Novel bile-based liquid biopsy approach for a cancer with high unmet need in early detection (BTC typically presents at late stage). Multi-cohort validation (n=203 total) with practical diagnostic combination (miR-196a + CA19-9 + CEA = AUROC 0.88) and early-stage signal for miR-196a. Bile biopsy route offers unique proximity advantage over plasma-based assays for biliary malignancies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.